Monopar Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview
07/05/2025 13:44
Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to show no change in quarterly revenue when it reports results on May 9 (estimated) for the period ending March 31 2025 ​LSEG's mean analyst estimate for Monopar Therapeutics Inc is for a loss of 68 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. ​ Wall Street's median 12-month price target for Monopar Therapeutics Inc is $60.00​, above​ its last closing price of $38.78. ​​​ Previous quarterly performance (using preferred earnings measure in US dollars). ​
| QUARTER ENDING | STARMINESMARTESTIMATEÂŪ | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Dec. 31 2024 | -0.42 | -2.75 | Missed | -554.8 | |
| Sep. 30 2024 | -0.48 | -0.48 | -0.37 | Beat | 22.4 |
| Jun. 30 2024 | -0.47 | -0.47 | -0.50 | Missed | -7.1​ |
| Mar. 31 2024 | -0.60 | -0.60 | -0.50 | Beat | 16.7 |
| ​​Dec. 31 2023 | -0.77 | -0.60 | Beat | 22.6 | |
| Sep. 30 2023 | -0.75 | -0.85 | -0.70 | Beat | 17.6​ |
| Jun. 30 2023 | -0.89 | -0.92 | -0.80 | Beat | 13 |
| Mar. 31 2023 | -1.11 | -1.11 | -0.95 | Beat | 14.4 |
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla